Abstract

Scientists from the Institute of Pharmacy and Biomedical Science at the University of Strathclyde confirm the ability of PLGA polymeric nanoparticles in a dry powder form to successfully deliver an encapsulated antigen payload intranasally for uptake in cells residing in the deep lungs infected by Mycobacterium tuberculosis. Using the NanoAssemblr® Benchtop to synthesize PLGA nanoparticles with a H56 tuberculosis (TB) antigen, the particles were applied to three macrophage cell lines and functioned as a mucosal booster in a prime-pull immunization protocol demonstrating a high retention of antigen immunogenicity. Observations in antigen uptake, processing, and relevant T-cell mediated immune responses against Mycobacterium tuberculosis were outlined having emphasis on the significance of T cell location in relation to the infected macrophages as a factor affecting the efficacy of novel vaccines. This research serves as evidence of the NanoAssemblr® platform's ability to drive future studies toward the development of novel subunit vaccines against tuberculosis and paves the way for further investigations on the capacity of PLGA nanoparticles to function as vaccine boosters.

Investigating Prime-Pull Vaccination through a Combination of Parenteral Vaccination and Intranasal Boosting

Abstract

Advanced Search

Browse by Category

related content

Microfluidic-assisted Preparation of RGD-decorated Nanoparticles: Exploring Integrin-facilitated Uptake in Cancer Cell Lines

A Lipid-encapsulated mRNA Encoding a Potently Neutralizing Human Monoclonal Antibody Protects Against Chikungunya Infection